Khan AM, Lin P, Kamdar N, Mahmoudi E, Latham-Mintus K, Kobayashi L, Clarke P. Location matters: the role of the neighborhood environment for incident cardiometabolic disease in adults aging with physical disability. Am J Health Promot. 2024 Jan 18. doi: 10.1177/08901171241228017
Hillmen P, Xie J, Yong A, Waweru C, Sorof TA, Goyal RK, Davis KL. Real-world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK. EJHaem. 2021 May;2(2):219-27. doi: 10.1002/jha2.174
Ko DT, Khan AM, Kotrri G, Austin PC, Wijeysundera HC, Koh M, Chu A, Jackevicius CA, Lawler PR, Tu JV. Eligibility, clinical outcomes, and budget impact of PCSK9 inhibitor adoption: the CANHEART PCSK9 study. J Am Heart Assoc. 2018 Nov 6;7(21):e010007. doi: 10.1161/JAHA.118.010007
Patorno E, Glynn RJ, Hernandez-Diaz S, Avorn J, Wahl PM, Bohn RL, Mines D, Liu J, Schneeweiss S. Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings. J Am Heart Assoc. 2013 Jul 30;2(4):e000208. doi: 10.1161/JAHA.113.000208.
Hahn EJ, Rayens MK, Warnick TA, Chirila C, Rasnake RT, Paul TP, Christie D. A controlled trial of a quit and win contest. Am J Health Promot. 2005 Nov 1;20(2):117-26.